Summary
Other Scenarios:
- OSIP - JNJ
- OSIP - PFE
- JNJ - WPI
- PFE - WPI
| Buyer: | OSI Pharmaceuticals, Inc. (OSIP) | Last Price: | 50.27 | Market Cap.: | 2.92B |
|---|---|---|---|---|---|
| Target: | Watson Pharmaceuticals, Inc. (WPI) | Last Price: | 27.61 | Market Cap.: | 2.86B |
Lines of Business Summary:
- OSI Pharmaceuticals, Inc. (OSIP) competes in 1 industry and 19 product/service groups
- Watson Pharmaceuticals, Inc. (WPI) competes in 1 industry and 282 product/service groups
- A combined entity will have 0% Product/Service Group overlap
- OSI Pharmaceuticals, Inc. (OSIP) has 0 and Watson Pharmaceuticals, Inc. (WPI) has 4 customers that derive significant revenue from each. They share 0 in common.
Product Summary:
Overlap & Complementary Sectors
| Sector | Buyer | Target | # of Focused Companies |
|---|---|---|---|
Healthcare |
|
|
933 |
Biopharmaceuticals |
|
|
381 |
|
Healthcare Services |
|
154 | |
|
Medical Devices |
|
|
253 |
|
Nutritional Health |
|
29 | |
|
Outsourced Services |
|
68 |
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Sample Products in Similar Lines of Business |
Sample Products in Complementary Lines of Business |
||
Buyer (Total: 15)
|
Target (Total: 313)
|
Buyer
|
Target
|
Business Relationship Summary:
Top Key Suppliers |
Top Key Customers |
||
Buyer (Total: 6)
|
Target (Total: 7)
|
Buyer (Total: 3)
|
Target (Total: 11)
|
Key Financial Summary:
Key Metrics
| Buyer | Target | |
|---|---|---|
| Number of Employees | 554 | 5,830 |
| Revenue Per Employee | 658,891.9 | 409,152.5 |
| Total Revenue | 100.4 | 594.7 |
| Total Expenses | 64.4 | 532.6 |
Other Revenue
|
0.0 | 0.0 |
|
Cost of Revenue
|
2.1 | 346.4 |
|
SG&A Expense
|
24.8 | 112.5 |
|
Research & Development
|
29.5 | 35.7 |
|
Other Operating Expense
|
0.0 | -6.1 |
|
Operating Income
|
36.0 | 62.1 |
|
Unusual Income
|
7.5 | 0.0 |
|
LT Debt to Capital
|
50.96 | 35.03 |
|
Fwd P/E
|
29.76 | 20.76 |
|
Fwd P/Rev
|
8.45 | 1.13 |
| Book Value | 110.6 | 1,807.0 |
|
Curr Portion of LTD/Cap Lease
|
150.0 | 6.6 |
Individual Company Summary
Focused
Buyer
Focused ():
Healthcare > Biopharmaceuticals > Oncology
Target
Focused ():
Healthcare > Biopharmaceuticals
Business Description
Buyer
OSI Pharmaceuticals, Inc. is a biotechnology company primarily focused on the discovery, development and commercialization of molecular targeted therapies addressing unmet medical needs in oncology, ophthalmology and diabetes. The Company?s primary focus is oncology and its flagship product is Tarceva (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor (EGFR). OSI Pharmaceuticals, Inc. also has research and development programs in diabetes and obesity, which are conducted through Prosidion Limited, the Company?s United Kingdom subsidiary. On November 6, 2006, the Company announced its intention to divest its eye disease business.
Target
Watson Pharmaceuticals, Inc. (Watson) is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent (generic) pharmaceutical products. Watson operates manufacturing, distribution, research and development, and administrative facilities primarily in the United States. As of December 31, 2006, the Company marketed more than 150 generic pharmaceutical products and more than 20 brand pharmaceutical products. The Company operates in two segments: generic and brand. In April 2006, Watson acquired Sekhsaria Chemicals Ltd., which provides process research and development and contract manufacturing services to the global pharmaceutical industry, including the development and manufacture of active pharmaceutical ingredients (API) and related intermediates. On November 3, 2006, Watson acquired Andrx Corporation.
Deal Summary
Key Ratios
| Buyer | Target | |
|---|---|---|
|
Gross Margin %
|
88.4 | 38.1 |
|
Operating Margin %
|
-42.87 | -11.66 |
|
Quick Ratio
|
1.41 | 1.07 |
|
Current Ratio
|
1.69 | 2.85 |
|
Coverage Ratio
|
-0.05 | 0.1 |
| Total Assets | 533.1 | 3,455.3 |
| Return on Equity % | -124.96 | -21.38 |
| Return on Assets % | -25.94 | -11.18 |
|
Cash+ ST Inv. Per Share
|
4.31 | 1.24 |
| Total Debt | 265.0 | 980.9 |
| Total Debt to Equity % | 239.49 | 54.29 |
| Total Debt to Tangible Equity % | 403.89 | 345.36 |
|
Debt to Asset %
|
49.71 | 28.39 |
Product Summary
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
Biopharmaceuticals |
|
|
|
Allergies
The Allergies Subsector includes therapeutics that treat exaggerated immune reaction induced by exposure to a foreign substance.
|
|
|
|
Cardiovascular System
The Cardiovascular System Subsector includes therapeutics that treat disorders affecting the heart and blood vessels.
|
|
|
|
Dermatology
The Dermatology Subsector includes therapeutics that treat disorders affecting the skin.
|
|
|
|
Digestive System
The Digestive System Subsector includes therapeutics that treat disorders affecting the digestive system.
|
|
|
|
Endocrinology/Metabolism
The Endocrinology/Metabolism Subsector includes therapeutics that treat metabolic disorders and conditions resulting from the dysfunction of hormone secreting glands.
|
|
|
|
Hematology
The Hematology Subsector includes therapeutics that treat blood-based diseases and disorders.
|
|
|
|
Immunology
The Immunology Subsector includes therapeutics that treat disorders affecting the immune system.
|
|
|
|
Infectious Diseases
The Infectious Diseases Subsector includes therapeutics that treat diseases caused by the invasion and reproduction of microorganisms in the body.
|
|
|
|
Musculoskeletal System
The Musculoskeletal System Subsector includes therapeutics that treat disorders of the bones, joints, ligaments, tendons, and soft tissue involved with them.
|
|
|
|
Neurology
The Neurology Subsector includes therapeutics that treat disorders of the central nervous system, including the brain, spinal cord, and nerves.
|
|
|
|
Obstetrics/Gynecology
The Obstetrics/Gynecology Subsector includes therapeutics that treat female genital disorders, pregnancy, and childbirth.
|
|
|
|
Oncology
The Oncology Subsector includes therapeutics that treat and manage various types of cancer and related complications.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes therapeutics that treat eye disorders, infections, inflammations and irritations.
|
|
|
|
Pain Management
The Pain Management Subsector includes therapeutics that treat and management pain.
|
|
|
|
Respiratory System
The Respiratory System Subsector includes therapeutics that treat disorders affecting both the upper and lower respiratory tract, including the nose, throat, larynx, trachea, bronchi, and lungs.
|
|
|
|
Surgery
The Surgery Subsector includes therapeutics that treat complications associated with surgical procedures.
|
|
|
|
Toxicology
The Toxicology Subsector includes therapeutics that treat harmful effects from exposure to toxic substances; narcotics, nicotine and alcohol withdrawal therapeutics are also included in this sector.
|
|
|
|
Urology
The Urology Subsector includes therapeutics that treat diseases of the kidney, urinary tract, bladder, and the male reproductive system.
|
|
|
|
Weight Management
The Weight Management Subsectors includes herapeutics that treat and manage weight disorders.
|
|
|
|
Wound Management
The Wound Management Subsector includes therapeutics that treat cuts, abrasions, and burns from trauma or diseases.
|
|
|
|
Healthcare Services |
|
|
|
Distributors
The Distributors Subsector is comprised of companies that distribute a wide variety of healthcare products, equipment and supplies to healthcare service providers and institutions.
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery
The Drug Delivery Subsector includes medical devices that facilitate the delivery of medications through different anatomical entryways, including blood vessels, skin, the mouth, and the lungs. Common devices in this sector include vascular access catheters, needles, implants, and inhalers.
|
|
|
|
Medical Supplies
The Medical Supplies Subsector includes basic and consumable products that are widely used in healthcare settings.
|
|
|
|
Ophthalmology
The Ophthalmology Subsector includes medical devices that diagnose and treat eye disorders.
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements
The Dietary/Naturopathic Subsector includes nutritional biochemicals and nutrients derived from natural sources that are intended to support health.
|
|
|
|
Outsourced Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Development/Manufacturing Services
The Development/Manufacturing Services Subsector includes companies that provide research, development, manufacturing, sales and marketing to biopharmaceutical and medical device companies.
|
|
|
|
Drug Delivery Technology
The Drug Delivery Technology Subsector includes companies that develop novel delivery methods for therapeutics.
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Product Details
| Sector | Buyer | Target |
|---|---|---|
|
Healthcare |
|
|
|
Biopharmaceuticals |
|
|
Allergies |
|
|
Dermatology |
|
|
|
Antihistamines
Products that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Ophthalmology |
|
|
|
Antihistamines
Therapeutics that inhibit inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Upper Respiratory |
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and relieve or prevent coughs.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat allergic reactions by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Target Products:
|
|
|
|
Cardiovascular System |
|
|
|
Heart Disorders |
|
|
|
Angina |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat chest pains by inhibiting stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat chest pains by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Arrhythmia |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat abnormal rhythm of the heart beat by inhibiting the stimulation of beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Potassium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of potassium into heart muscle cells.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat abnormal rhythm of the heart by preventing the entry of sodium into heart muscle cells.
Target Products:
|
|
|
|
Heart Failure (HF) |
|
|
|
Adjunctive Treatments |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that assist in the primary treatment of the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat the ineffective pumping of the heart by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat the ineffective pumping of the heart by blocking beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of fluid by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Myocardial Infarction (MI) |
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat irreversible damage to the heart muscle by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat irreversible damage to the heart muscle by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat irreversible damage to the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Target Products:
|
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat irreversible damage to the heart muscle by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Vascular Disorders |
|
|
|
Atherosclerosis |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that treat the narrowing or hardening of the arteries by preventing the synthesis of cholesterol.
Target Products:
|
|
|
|
Coronary Artery Disease (CAD) |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat the narrowing or hardening of the coronary arteries of the heart muscle by blocking the influx of calcium ions into heart muscle cells.
Target Products:
|
|
|
|
Hypertension |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat high blood pressure by stimulating the alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that treat high blood pressure by blocking alpha adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)/Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking alpha and beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Calcium Channel Blockers
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and preventing the entry of calcium into heart muscle cells.
Target Products:
|
|
|
|
Angiotensin Converting Enzyme Inhibitors (ACE Inhibitors)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by inhibiting the renin-angiotensin system and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle.
Target Products:
|
|
|
|
Beta Receptor Blocking Agents (Beta Blockers)/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Calcium Channel Blocking Agents
Therapeutics that treat high blood pressure by blocking the beta adrenergic receptors of the heart muscle and increasing the excretion of sodium ions, potassium ions, and water through urine.
Target Products:
|
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of water and sodium, but not potassium in urine.
Target Products:
|
|
|
|
Sulfonamide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat high blood pressure by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Vasodilatory Agents
Therapeutics that treat high blood pressure by causing relaxation of the blood vessels.
Target Products:
|
|
|
|
Peripheral Vascular Disease |
|
|
|
Blood Viscosity Reducing Agents
Therapeutics that treat arterial obstruction outside of the heart by altering the flow of red blood cells.
Target Products:
|
|
|
|
Stroke |
|
|
|
Calcium Channel Blocking Agents
Therapeutics that prevent strokes by by blocking the influx of calcium ions into vascular cells.
Target Products:
|
|
|
|
Tremors |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that prevent or treat involuntary trembling by blocking the beta adrenergic receptors in muscle tissue.
Target Products:
|
|
|
|
Dermatology |
|
|
|
Acne |
|
|
|
Vulgaris |
|
|
|
Estrogens/Progestins
Therapeutics that treat acne by providing estrogen and progestin.
Target Products:
|
|
|
|
Keratolytic Agents
Therapeutics that soften, separate, and cause the shedding of skin.
Target Products:
|
|
|
|
Hair Disorders |
|
|
|
Alopecia (Hair Loss) |
|
|
|
5 Alpha Reductase Inhibitors
Therapeutics that treat hair loss by blocking the action of an enzyme that converts testosterone to a testosterone derivative.
Target Products:
|
|
|
|
Lesion/Scaling Disorders |
|
|
|
Dermatitis |
|
|
|
Atopic (Eczema) |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat atopic dermatoses by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Seborrheic (Dandruff) |
|
|
|
Anti-Mitotic Agents
Therapeutics that block the mitotic division of cells.
Target Products:
|
|
|
|
Antifungal Agents |
|
|
|
Imidazoles
Therapeutics that treat and prevent skin diseases caused by fungi.
Target Products:
|
|
|
|
Dermatoses |
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that counteract or suppress inflammation by inhibiting the accumulation of inflammatory cells like leucocytes and macrophages at the inflammation site.
Target Products:
|
|
|
|
Diaper Rash |
|
|
|
Zinc Oxide
Therapeutics that treat diaper rash by forming a protective barrier against the skin.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Gall Bladder Disorders |
|
|
|
Cholelithiasis (Gallstones) |
|
|
|
Anticholelithic Agents
Therapeutics that treat gall stones by decreasing the liver's cholesterol synthesis and secretion.
Target Products:
|
|
|
|
Gastrointestinal Tract Disorders |
|
|
|
Gastroduodenal Disorders |
|
|
|
Peptic Ulcers |
|
|
|
Duodenal |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Ulcer Adhering Agents
Therapeutics that treat peptic ulcers by binding to it and protecting it from further damage.
Target Products:
|
|
|
|
Gastric |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat peptic ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat peptic ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Zollinger-Ellison Syndrome |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat ulcers by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat ulcers by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroesophageal Disorders |
|
|
|
Abdominal Gas |
|
|
|
Acid Neutralizing Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the acidity of the stomach as well as lowering the surface tension of gas bubbles in the bowels.
Target Products:
|
|
|
|
Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat abdominal gas by reducing the surface tension of gas bubbles in the bowels.
Target Products:
|
|
|
|
Acid Indigestion/Heartburn |
|
|
|
Acid Neutralizing Agents
Therapeutics that treat heartburn by neutralizing stomach acid.
Target Products:
|
|
|
|
Acid Neutralizing Agents/Gas Bubble Surface Tension Reducing Agents
Therapeutics that treat indigestion by neutralizing the stomach acid as well as lowering the surface tension of the gas bubbles in the bowels.
Target Products:
|
|
|
|
H2 Receptor Antagonists
Therapeutics that treat indigestion by blocking the action of histamine at the H2 receptors.
Target Products:
|
|
|
|
Erosive Esophagitis |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Erosive Esophagitis by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Erosive Esophagus by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Gastroesophageal Reflux Disease (GERD) |
|
|
|
H2 Receptor Antagonists
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the actions of receptors responsible for triggering acid release into the stomach.
Target Products:
|
|
|
|
Proton Pump Inhibitors
Therapeutics that treat Gastroesophageal Reflux Disease by inhibiting the membrane protein involved in the final steps of triggering acid release into the stomach.
Target Products:
|
|
|
|
Nausea/Vomiting |
|
|
|
Antiemetic Agents
Therapeutics that treat nausea or vomiting by acting locally on the hyperactive gastrointestinal wall.
Target Products:
|
|
|
|
Serotonin Receptor Antagonists
Therapeutics that treat nausea and vomiting by blocking the serotonin receptors.
Target Products:
|
|
|
|
Intestinal Disorders |
|
|
|
Constipation |
|
|
|
Chronic |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Target Products:
|
|
|
|
Impacted Bowels |
|
|
|
Hyperosmotic Agents
Therapeutics that treat constipation by causing fluid overload, which in turn induces liquid stool within a short period of time.
Target Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Target Products:
|
|
|
|
Stool Softeners
Therapeutics that treat constipation by increasing the absorption of moisture into feces to form a softer body.
Target Products:
|
|
|
|
Irregular Bowel Movements |
|
|
|
Bulk-Forming Agents
Therapeutics that treat constipation by stimulating the formation of bodies of feces that are able to be passed through the bowels.
Target Products:
|
|
|
|
Stimulants
Therapeutics that treat constipation by stimulating the contraction of bowels by addition of fiber or other substances.
Target Products:
|
|
|
|
Diarrhea |
|
|
|
Adsorbents
Therapeutics that treat diarrhea by promoting the uptake of water from the intestines.
Target Products:
|
|
|
|
Antiperistaltic Agents
Therapeutics that treat diarrhea by inhibiting the wavelike motion of the digestive tract.
Target Products:
|
|
|
|
Antisecretory Agents
Therapeutics that treat diarrhea by bringing fluid movement within the intestine to normal levels.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat ulcerative colitis by inhibiting the actions of the two enzymes, cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Irritable Bowel Syndrome (IBS) |
|
|
|
Anticholinergic Agents
Therapeutics that treat irritable bowel syndrome by decreasing the liver's cholesterol synthesis and secretion.
Target Products:
|
|
|
|
Rectal Disorders |
|
|
|
Hemorrhoids |
|
|
|
Alpha Adrenergic Receptor Agonists
Therapeutics that treat hemorrhoids by stimulating the alpha adrenergic receptors.
Target Products:
|
|
|
|
Liver Disorders |
|
|
|
Cirrhosis |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Endocrinology/Metabolism |
|
|
|
Diabetes |
|
|
|
Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes |
|
|
|
Biguanides
Therapeutics that treat abnormally high blood glucose levels by decreasing the production of glucose in the liver, decreasing intestinal absorption of glucose and increasing peripheral uptake and utilization of glucose.
Target Products:
|
|
|
|
Biguanides/Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Therapeutics that control high blood sugar by stimulating the release of insulin as well as sensitizing organs to insulin.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Non-Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that treat non-insulin dependent diabetes by stimulating the secretion of insulin.
Target Products:
|
|
|
|
Peroxisome Proliferator-Activated Receptor Agonists (PPAR Agonists)
Products that sensitizes organs to insulin.
Target Products:
|
|
|
|
General Hormone Treatments |
|
|
|
Prednisolones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Prednisones
Therapeutics that treat inflammation by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Intermediary Metabolism Disorders |
|
|
|
Gout |
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that counteract or suppress inflammation preventing cyclooxygenase activity.
Target Products:
|
|
|
|
Urate Crystalization Inhibitors
Therapeutics that treat gouty arthritis by preventing the deposition of urate crystals in the joints.
Target Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys.
Target Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the resorption of urate from the kidneys and prevent the precipitation of urate in the joint.
Target Products:
|
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Reproductive Disorders |
|
|
|
Amenorrhea |
|
|
|
Progestins
Female sex hormone necessary for the development of the female reproductive system.
Target Products:
|
|
|
|
Hypoestrogenism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Male |
|
|
|
Androgens
Therapeutics that are male sex hormones.
Target Products:
|
|
|
|
Menopause |
|
|
|
Estrogens
Therapeutics that are female sex hormones.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of endocrinology disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of hematological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Red Blood Cell (RBC) Disorders |
|
|
|
Anemia |
|
|
|
Iron Supplements
Therapeutics that treat conditions characterized by reduced delivery of oxygen to body tissues caused by iron deficiency by replacing missing iron.
Target Products:
|
|
|
|
Serum Factor Disorders |
|
|
|
Hypercholesterolemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Hyperglycemia |
|
|
|
Insulin Stimulating Agents (Sulfonylureas)
Therapeutics that stimulate the secretion of insulin.
Target Products:
|
|
|
|
Hyperlipidemia |
|
|
|
HMG CoA Reductase Inhibitors (Statins)
Therapeutics that block cholesterol synthesis by binding a key enzyme in the synthesis process.
Target Products:
|
|
|
|
Plasma Triglyceride Reducing Agents (Fibrate Compounds)
Therapeutics that reduce the levels of very low-density lipoprotein and increase levels of high-density lipoproteins.
Target Products:
|
|
|
|
Hyperuricemia |
|
|
|
Urate Resorption Inhibitors
Therapeutics that prevents the resorption of urate within the kidneys.
Target Products:
|
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat hyperuricemia by preventing the conversion of hypoxanthine to uric acid.
Target Products:
|
|
|
|
Hypokalemia |
|
|
|
Potassium Supplements
Therapeutics that treat hypokalemia by providing potassium to the body.
Target Products:
|
|
|
|
Thrombocyte (Platelet) Disorders |
|
|
|
Thrombocythemia |
|
|
|
Megakaryocyte Maturation Inhibitors
Therapeutics that prevents the maturation of platelet producing cells.
Target Products:
|
|
|
|
Immunology |
|
|
|
Autoimmune Disorders |
|
|
|
Arthritis |
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat chronic inflammation of the joints by inhibiting a full immune response.
Target Products:
|
|
|
|
Inflammatory Bowel Disease (IBD) |
|
|
|
Ulcerative Colitis |
|
|
|
Cyclooxygenase Inhibitors (COX Inhibitors)/Lipoxygenase Inhibitors
Therapeutics that treat inflammation of the colon and rectum by blocking the action of cyclooxygenase and lipoxygenase.
Target Products:
|
|
|
|
Lupus Erythematosus |
|
|
|
Systemic (SLE) |
|
|
|
Hormonal
Therapeutics that treat systemic lupus with hormones.
Target Products:
|
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat a neurodegenerative disease characterized by the gradual accumulation of plaques on the nerve sheaths an enzyme that inhibits the proliferation of cells.
Buyer Products:
|
|
|
|
Infectious Diseases |
|
|
|
Bacterial |
|
|
|
Antibacterial Agents |
|
|
|
Broad Spectrum |
|
|
|
Antibiotics |
|
|
|
Cephalosporin Derivatives
Therapeutics that treat a wide variety of infections by inhibiting bacterial cell wall synthesis.
Target Products:
|
|
|
|
Lincosamides
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis.
Target Products:
|
|
|
|
Macrolides
Therapeutics that treat a wide variety of infections by inhibiting RNA-dependent bacterial protein synthesis.
Target Products:
|
|
|
|
Nitroimidazoles
Therapeutics that treat a wide variety of infections by inhibiting bacterial protein synthesis and causing cell death.
Target Products:
|
|
|
|
Sulfonamides
Therapeutics that treat a wide variety of bacterial infections by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat a wide variety of infections by inhibiting protein synthesis and also causing alterations in cytoplasmic membranes.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Sulfonamides
Therapeutics that treat specific bacterial infections by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skin/Soft Tissue Infections |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections of non-skeletal tissue usually involving fat, muscle, and skin by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Urology |
|
|
|
Urinary Tract Infections (UTI) |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Nitrofurantoins
Therapeutics that treat bacterial infections of the urinary tract by inactivating/altering bacterial proteins and other macromolecules.
Target Products:
|
|
|
|
Trimethoprim
Therapeutics that treat bacterial infections of the urethra, urinary bladder, ureters, and kidneys by blocking the action of bacterial dihydrofolate reductase.
Target Products:
|
|
|
|
Mycological (Fungal) |
|
|
|
Antifungal Agents |
|
|
|
Narrow Spectrum |
|
|
|
Dermatology |
|
|
|
Onychomycosis (Nail) |
|
|
|
Amine Derivatives |
|
|
|
Allyl
Therapeutics that treat fungal infections of the nail caused by yeast by causing a deficiency in the cell wall.
Target Products:
|
|
|
|
Tinea Corporis (Ringworm) |
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the skin characterized by scaly, red rings by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Cruris (Jock Itch) |
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the groin and perineum by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Tinea Pedis |
|
|
|
Thiocarbamates
Therapeutics that treat fungal infections of the feet by stunting the growth of the branching filaments.
Target Products:
|
|
|
|
Urology |
|
|
|
Vaginal Candidiasis |
|
|
|
Azoles |
|
|
|
Imidazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Triazoles
Therapeutics that treat fungal infections of the female reproductive organ caused by yeast by increasing permeability of the cell wall and causing a toxic build up of hydrogen peroxide.
Target Products:
|
|
|
|
Protozoal |
|
|
|
Antiprotozoal Agents |
|
|
|
Broad Spectrum |
|
|
|
Nitroimidazoles
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Tetracyclines
Therapeutics that treat infections caused by a wide variety of unicellular organisms by inhibiting protein synthesis and causing cell death.
Target Products:
|
|
|
|
Narrow Spectrum |
|
|
|
Malaria |
|
|
|
Quinines
Therapeutics that treat parasitic infections caused by Plasmodia in red blood cells by disrupting replication and transcription.
Target Products:
|
|
|
|
Viral |
|
|
|
DNA Viruses |
|
|
|
Herpesvirus |
|
|
|
Herpes Labialis (Cold Sores) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Herpes Simplex Type 1 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurrent cold sores and fever blisters by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Herpes Simplex Type 2 |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections characterized by recurring outbreaks of painful genital lesions by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Varicella Zoster |
|
|
|
Herpes Zoster (Shingles) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause shingles in adults by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Varicella (Chickenpox) |
|
|
|
Purine Nucleoside Analogs
Therapeutics that treat viral infections that cause chicken pox in children by inhibiting replication of viral DNA by incorporating themselves into growing viral DNA stands.
Target Products:
|
|
|
|
Papillomavirus |
|
|
|
Genital Warts |
|
|
|
Podophyllins
Therapeutics that treat viral infections that cause genital warts by eroding skin lesions.
Target Products:
|
|
|
|
Musculoskeletal System |
|
|
|
Skeletal Disorders |
|
|
|
Bone Disorders |
|
|
|
Osteoporosis |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat osteoporosis by providing female hormones which results in a decrease in the rate of bone loss due to osteoclasts.
Target Products:
|
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat osteoporosis by preventing loss of bone mass due to osteoclasts.
Target Products:
|
|
|
|
Paget`s Disease |
|
|
|
Osteoclast Bone Resorption Inhibitors
Therapeutics that treat paget's disease by inhibiting the loss of bone material by osteoclasts.
Target Products:
|
|
|
|
Joint Disorders |
|
|
|
Ankylosing Spondylitis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Gouty Arthritis |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by inhibiting cyclooxygenase activity.
Target Products:
|
|
|
|
Urate Crystalization Inhibitors
Therapeutics that treat gouty arthritis by preventing the deposition of urate crystals in the joints.
Target Products:
|
|
|
|
Urate Resorption Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate.
Target Products:
|
|
|
|
Urate Resorption Inhibitors/Urate Crystallization Inhibitors
Therapeutics that treat gouty arthritis by preventing the active reabsorption of urate at the renal tubule thus increasing the excretion of urinary acid and lowering serum concentrations of urate as well as preventing the deposition of excess urate crystals in the joints.
Target Products:
|
|
|
|
Osteoarthritis (OA) |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat inflammation by specifically inhibiting the action of cyclooxygenase-2.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat inflammation by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat inflammation by preventing the accumulation of Substance P at the inflammation sites.
Target Products:
|
|
|
|
Rheumatoid Arthritis (RA) |
|
|
|
Analgesics |
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by selectively blocking cyclooxygenase 2 activity.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain associated with chronic inflammation of the joints by blocking cyclooxygenase activity.
Target Products:
|
|
|
|
Immunotherapy |
|
|
|
Immunosuppressants
Therapeutics that treat rheumatoid arthritis by suppressing the immune system.
Target Products:
|
|
|
|
Neurology |
|
|
|
Neurological Disorders |
|
|
|
Alzheimer`s Disease |
|
|
|
Acetylcholinesterase Inhibitors
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine.
Target Products:
|
|
|
|
Acetylcholinesterase Inhibitors/Nicotinic Receptor Modulators
Therapeutics that treat Alzheimer's Disease by preventing the breakdown of a the neurotransmitter, acetylcholine, and by modulating the receptor that binds nicotine.
Target Products:
|
|
|
|
Epilepsy |
|
|
|
Partial Seizures |
|
|
|
Complex |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid, which prevent nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents
Therapeutics that treat complex partial seizures by blocking the sodium channels which in turn block the conductance of neural impulses through the brain.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat complex partial seizures by preventing the uptake of gamma-aminobutyric acid as well as blocking the sodium channels which in turn block the conductance of electrical impulses through the brain.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Barbiturates
Therapeutics that treat complex partial seizures by decreasing excitability of neurons.
Target Products:
|
|
|
|
Simple |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat simple partial seizures by preventing the uptake of gamma-aminobutyric acid which prevents nerve activation.
Target Products:
|
|
|
|
Sodium Channel Blocking Agents/Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat simple partial seizure by both preventing the uptake of gamma-aminobutyric acid which prevents nerve activation as well as blocking the sodium channels which in turn block the conductance of neural impulses.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Barbiturates
Therapeutics that treat simple partial seizures by decreasing excitability of neurons.
Target Products:
|
|
|
|
Primary Generalized Seizures |
|
|
|
Absence (Petit Mal) |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Petit Mal Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Akinetic Pattern |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Akinetic
Pattern Seizures by preventing the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Myoclonic |
|
|
|
Adjunctive Therapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevent nerve activation.
Target Products:
|
|
|
|
Monotherapy |
|
|
|
Gamma-Aminobutyric Acid (GABA) Reuptake Inhibitors
Therapeutics that treat Myoclonic Seizures by inhibiting the uptake of molecules that prevents nerve activation.
Target Products:
|
|
|
|
Tonic-Clonic (Grand Mal) |
|
|
|
Barbiturates
Therapeutics that treat tonic clonic seizures by acting as sedatives through nonselective suppression of central nervous system activities.
Target Products:
|
|
|
|
Headaches |
|
|
|
Tension Type |
|
|
|
Barbiturates/Analgesics/Antipyretics/Opioids/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons, decreasing pain by inhibiting the production of prostaglandins as well as stimulating the opioid receptors.
Target Products:
|
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons and decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Opioids/Stimulants
Therapeutics that treat pain by depressing neural activity, preventing inflammation and fever, altering the perception of and emotional response to pain, and stimulating the central nervous system.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Stimulants
Therapeutics that treat tension type headaches by decreasing the excitability of neurons as well as decreasing pain by inhibiting the production of prostaglandins.
Target Products:
|
|
|
|
Vascular (Migraine) |
|
|
|
Prophylactic Treatments |
|
|
|
Beta Adrenergic Receptor Blocking Agents (Beta Blockers)
Therapeutics that treat Migraine by inhibiting stimulation of beta adrenergic receptors.
Target Products:
|
|
|
|
Motion Sickness |
|
|
|
Anticholinergic Agents
Therapeutics that treat motion sickness by selectively deterring actions of the involuntary nervous system.
Target Products:
|
|
|
|
Antivertigo Agents
Therapeutics that prevent the sensation of motion.
Target Products:
|
|
|
|
Spasticity (Spinal Shock) |
|
|
|
Aspartic Receptor Antagonists/Glutamic Receptor Antagonists
Therapeutics that treat Spinal Shock by blocking the receptors for aspartic acid and glutamic acid, both excitatory neurotransmitters.
Target Products:
|
|
|
|
Neuromuscular Disorders |
|
|
|
Multiple Sclerosis (MS) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat multiple sclerosis by inhibiting a key enzyme involved with cell division.
Buyer Products:
|
|
|
|
Myasthenia Gravis (MG) |
|
|
|
Cholinesterase Inhibitors
Therapeutics that treat Myasthenia Gravis by maintaining the transmission of nerve impulses by inhibiting the enzyme that breaks down acetylcholine.
Target Products:
|
|
|
|
Parkinson`s Disease (PD) |
|
|
|
Adjunctive Treatments |
|
|
|
Cholinergic Receptor Blocking Agents
Therapeutics that assist in the treatment of the disorder involving nerve cell loss in portions of the brain that leads to uncontrolled tremors, abnormal posture and speech problems by blocking acetylcholine receptors on neurons.
Target Products:
|
|
|
|
Psychiatric Disorders |
|
|
|
Anxiety |
|
|
|
Generalized Anxiety Disorder (GAD) |
|
|
|
Antihistamines
Therapeutics that treat anxiety by blocking the action of histamines.
Target Products:
|
|
|
|
Carbamate Derivatives
Therapeutics that treat anxiety by blocking the NMDA receptor thus blocking the effects of excitatory amino acids and suppressing seizure activity.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat anxiety by blocking dopamine receptors.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents/Tricyclic Antidepressants
Therapeutic combinations that treat anxiety by blocking dopamine receptors as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat anxiety by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat anxiety by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat anxiety by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Obsessive Compulsive Disorder (OCD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Anxiety by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Panic Disorder |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat panic disorder by enhancing the inhibitory neurotransmitter action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat panic disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Post-Traumatic Stress Disorder (PTSD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat post traumatic stress disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Social Anxiety Disorder (SAD) |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat Social Anxiety Disorder by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Childhood/Adolescent Disorders |
|
|
|
Attention Deficit Disorder (ADD)/Attention Deficit Hyperactivity Disorder (ADHD) |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat attention deficit disorder by blocking the dopamine receptors.
Target Products:
|
|
|
|
Eating Disorders |
|
|
|
Bulimia |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat eating disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Mood Disorders |
|
|
|
Bipolar Disorders (Manic Depressive Disorders) |
|
|
|
Tricyclic Compounds
Therapeutics that treat bipolar disorders by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Depression |
|
|
|
Dopamine Receptor Blocking Agents/Tricyclic Antidepressants
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin and by blocking the receptor for dopamine.
Target Products:
|
|
|
|
Monoamine Oxidase (MAO) Inhibitors
Therapeutics that treat depression by inhibiting the activity of monoamine oxidase, which degrades neurotransmitters.
Target Products:
|
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat depression by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that treat depression by inhibiting the neuronal uptake of serotonin and norepinephrine.
Target Products:
|
|
|
|
Tetracyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine.
Target Products:
|
|
|
|
Tricyclic Compounds
Therapeutics that treat depression by increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Premenstrual Dysphoric Disorders |
|
|
|
Selective Serotonin Reuptake Inhibitors (SSRI)
Therapeutics that treat premenstrual dysphoric disorders by selectively preventing the removal of serotonin.
Target Products:
|
|
|
|
Schizophrenia |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat schizophrenia by blocking the dopamine receptors.
Target Products:
|
|
|
|
Dopamine Receptor Blocking Agents/Tricyclic Antidepressants
Therapeutic combinations that treat the disorder involving disturbances in thoughts, emotions and reasoning by blocking dopamine receptors as well as increasing the synaptic concentrations of norepinephrine and serotonin.
Target Products:
|
|
|
|
Sleep Disorders |
|
|
|
Insomnia |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat insomnia by enhancing the inhibitory action of gamma-aminobutyric acid.
Target Products:
|
|
|
|
Narcolepsy |
|
|
|
Dopamine Receptor Blocking Agents
Therapeutics that treat Narcolepsy by blocking the dopamine receptors.
Target Products:
|
|
|
|
Obstetrics/Gynecology |
|
|
|
Child Birth/Pregnancy |
|
|
|
Prevention (Contraception) |
|
|
|
Contraceptives (Birth Control) |
|
|
|
Estrogens
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Estrogens/Progestins
Therapeutics that prevent conception by decreasing the secretion of gonadotropin-releasing hormone in the hypothalamus, resulting in an anti-ovulatory effect.
Target Products:
|
|
|
|
Progestins
Contraceptive Therapeutics that are female sex hormone necessary for the development of the female reproductive system
Target Products:
|
|
|
|
Female Genital Disorders |
|
|
|
Infertility |
|
|
|
Hormonal Treatments |
|
|
|
Ovulation Stimulating Agents
Therapeutics that treat infertility by stimulating the ovaries to release a mature egg.
Target Products:
|
|
|
|
Ovarian |
|
|
|
Hypogonadism |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
These are female sex hormones.
Target Products:
|
|
|
|
Sexual Dysfunction |
|
|
|
Androgens
Therapeutics that treat female sexual dysfunction by providing male sex hormone, such as testosterone, that is important for the normal functioning of the female reproductive system.
Target Products:
|
|
|
|
Vulvovaginal |
|
|
|
Atrophy |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat disorders characterized by thinning of the vaginal walls with the female sex hormone estrogen.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of female reproductive disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Oncology |
|
|
|
Breast Cancer |
|
|
|
Metastatic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers of the breast that have spread beyond their original tumor site by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Palliative Agents |
|
|
|
Hormonal Treatments |
|
|
|
Estrogens
Therapeutics that treat and manage breast cancer in post-menopausal women by providing female hormones.
Target Products:
|
|
|
|
Digestive System |
|
|
|
Colon Cancer/Colorectal Cancer |
|
|
|
Metastatic |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage colorectal cancer by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Buyer Products:
|
|
|
|
Topoisomerase I Inhibitors
Therapeutics that treat and manage colorectal cancers by inhibiting a specific enzyme needed for transcription and replication of DNA.
Target Products:
|
|
|
|
Pancreatic Cancer |
|
|
|
Metastatic |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the pancreas by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Buyer Products:
|
|
|
|
Hematology |
|
|
|
Leukemia (White Blood Cell Cancer) |
|
|
|
Myeloid |
|
|
|
Acute |
|
|
|
Erythroleukemic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature red blood cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Monocytic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancers affecting mononuclear cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myeloblastic |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers affecting immature cells of the bone marrow by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Myelogenous (AML) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage rapidly progressing cancers of the myelogenous cells by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Promyelocytic (APL) |
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage promyelocytic leukemia by inhibiting a specific enzyme needed for transcription and replication of DNA.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy by preventing the formation of uric acid from xanthine.
Target Products:
|
|
|
|
Lymphoma (Lymphatic Cancer) |
|
|
|
Hodgkin`s Disease |
|
|
|
Palliative Agents |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat renal toxicity associated with chemotherapy for lymphoma characterized by the presence of Reed-Sternberg cells by preventing the formation of uric acid from xanthine.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer in early stages of clinical research where human subject is involved.
Buyer Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment and management of cancer and are currently in an early research or preclinical stage of development.
Buyer Products:
|
|
|
|
Respiratory System/Thoracic |
|
|
|
Lung Cancer |
|
|
|
Non Small Cell Lung Cancer (NSCLC) |
|
|
|
EGFR-TK Inhibitors/Monoclonal Antibodies
Therapeutics that treat lung cancer by blocking the tyrosine kinase enzyme and by binding to specific structures on the surface of the tumor and eliciting a reaction, which results in tumor degeneration.
Buyer Products:
|
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage cancers of the lung including squamous cell carcinoma, adenocarcinoma and large cell carcinoma by blocking the tyrosine kinase enzyme by switching off the signals from the epidermal growth factor receptors.
Buyer Products:
|
|
|
|
Urology |
|
|
|
Ovarian Cancer |
|
|
|
Adenocarcinoma |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage cancer of cells lining the ovary by interacting with DNA and inhibiting cell division.
Target Products:
|
|
|
|
Metastatic |
|
|
|
Epidermal Growth Factor Receptor Tyrosine Kinase (EGFR-TK) Inhibitors
Therapeutics that treat and manage ovarian cancers by blocking the action of tyrosine kinase enzyme through switching off the signals from the epidermal growth factor receptors, which promote cell growth.
Buyer Products:
|
|
|
|
Palliative Agents |
|
|
|
Alkylating Agents |
|
|
|
Platinum-Based Agents
Platinum containing therapeutics that treat and manage ovarian cancers by interacting with DNA and inhibiting cell division but are not curative.
Target Products:
|
|
|
|
Prostate Cancer |
|
|
|
Palliative Agents |
|
|
|
Estrogens
Therapeutics that treat and manage prostate cancer by inhibiting the secretion of luteinizing hormone and affecting the testes so as to decrease serum concentrations of testosterone but are not curative.
Target Products:
|
|
|
|
Gonadotropin Releasing Hormone (GnRH) Antagonists
Therapeutics that treat and manage primary tumors of the prostate gland by blocking the action of gonadotropin releasing hormone and thus decreasing levels of testosterone.
Target Products:
|
|
|
|
Topoisomerase II Inhibitors
Therapeutics that treat and manage cancer of the prostate gland by inhibiting a specific enzyme needed for transcription and replication of DNA but are not curative.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Degenerative Disorders |
|
|
|
Dry Eye |
|
|
|
Lubricants
Therapeutics that wet the eye and lubricate the eye.
Target Products:
|
|
|
|
Glaucoma |
|
|
|
Carbonic Anhydrase Inhibitors
Therapeutics that decrease the formation of the fluid of the eye.
Target Products:
|
|
|
|
Irritation/Inflammation |
|
|
|
Vasoconstricting Agents
Therapeutics that prevent inflammation by constricting the blood vessels.
Target Products:
|
|
|
|
Pain Management |
|
|
|
Narcotics |
|
|
|
Analgesics/Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alters the both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Barbiturates/Analgesics/Antipyretics/Opioids/Stimulants
Therapeutics that treat pain by depressing neural activity, preventing inflammation and fever, altering the perception of and emotional response to pain, and stimulating the central nervous system.
Target Products:
|
|
|
|
Barbiturates/Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Opioids/Stimulants
Therapeutics that treat pain by depressing neural activity, preventing inflammation and fever, altering the perception of and emotional response to pain, and stimulating the central nervous system.
Target Products:
|
|
|
|
Opioids
Therapeutics that treat pain by binding to certain nervous system receptors which alter both the perception of pain as well as the emotional response to pain.
Target Products:
|
|
|
|
Non-Narcotics |
|
|
|
Analgesics Combinations |
|
|
|
Analgesics/Antipyretics
Therapeutics that treat pain and fever by inhibiting the action of prostaglandins.
Target Products:
|
|
|
|
Barbiturates/Analgesics/Antipyretics/Stimulants
Therapeutic combinations that treat pain by depressing neural activity, preventing inflammation and fever, and stimulating the central nervous system.
Target Products:
|
|
|
|
Non-Steroidal Anti-Inflammatory Drugs (NSAID) |
|
|
|
Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)
Therapeutics that treat pain by specifically inhibiting the action of cyclooxygenase-2.
Target Products:
|
|
|
|
Non-Specific Cyclooxygenase Inhibitors (COX Inhibitors)
Therapeutics that treat pain by non-specifically inhibiting the action of cyclooxygenase.
Target Products:
|
|
|
|
Skeletal Muscle Relaxing Agents
Therapeutics that treat pain by depressing specific synaptic reflexes preferentially.
Target Products:
|
|
|
|
Steroidal Anti-Inflammatory Drugs (SAID)
Therapeutics that treat pain by preventing the accumulation of inflammatory cells, like macrophages and leukocytes to the inflammation sites.
Target Products:
|
|
|
|
Substance P Inhibitors
Therapeutics that treat pain by inhibiting the accumulation of Substance P at the inflammation site.
Target Products:
|
|
|
|
Respiratory System |
|
|
|
Lower Respiratory Tract Disorders (Lung Disorders) |
|
|
|
Asthma |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Bronchitis |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Bronchospasm |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Chronic Obstructive Pulmonary Disease (COPD) |
|
|
|
Acute Treatments |
|
|
|
Bronchodilators |
|
|
|
Beta Adrenergic Receptor Agonists
Therapeutics that cause dilation of the lung passages by supporting the actions of the adrenergic transmitters like epinephrine and norepinephrine.
Target Products:
|
|
|
|
Upper Respiratory Tract Disorders |
|
|
|
Coughs/Colds |
|
|
|
Amphetamines
Therapeutics that treat coughs and colds by helping to relieve nasal congestion.
Target Products:
|
|
|
|
Antihistamines
Therapeutics that inhibit the inflammation by blocking the action of histamines on tissues.
Target Products:
|
|
|
|
Antihistamines/Decongestants
Therapeutics that block the inflammatory action of histamines and reduces the amount of mucous build up.
Target Products:
|
|
|
|
Antihistamines/Decongestants/Antitussives
Therapeutics that treat coughs and colds by suppressing inflammation, reducing mucous build up, and relieving or preventing coughs.
Target Products:
|
|
|
|
Decongestants
Therapeutics that treat coughs and colds by reducing mucous build up.
Target Products:
|
|
|
|
Decongestants/Expectorants
Therapeutics that treat coughs and colds by reducing mucous build up and help in ejection of mucous.
Target Products:
|
|
|
|
Expectorants
Therapeutics that treat coughs and colds by helping in the ejection of mucous.
Target Products:
|
|
|
|
Nasal Dryness |
|
|
|
Moisturizing Agents
Therapeutics that treat nasal dryness by providing moisture to the nasal passages.
Target Products:
|
|
|
|
Surgery |
|
|
|
General |
|
|
|
Restlessness/Apprehension |
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat the nervousness which precedes surgery by increasing the action of gamma aminobutyric acid at the relevant neuroreceptors.
Target Products:
|
|
|
|
Toxicology |
|
|
|
Substance Abuse |
|
|
|
Withdrawal |
|
|
|
Alcohol |
|
|
|
Antihistamines
Therapeutics that treat alcohol withdrawal by blocking the H2 receptors and thus the effects of histamines.
Target Products:
|
|
|
|
Gamma-Aminobutyric Acid (GABA) Receptor Agonists
Therapeutics that treat alcohol withdrawal by increasing the effect of GABA at the relevant neuroreceptors.
Target Products:
|
|
|
|
Nicotine (Smoking Cessation) |
|
|
|
Nicotinic Receptor Agonists
Therapeutics that treat nicotine withdrawal by activating nicotine receptors thus reducing cravings for nicotine.
Target Products:
|
|
|
|
Serotonin/Norepinephrine Reuptake Inhibitors
Therapeutics that increase the concentration of several neurotransmitters in the brain by inhibiting their uptake.
Target Products:
|
|
|
|
Urology |
|
|
|
Male Genital Disorders |
|
|
|
Prostate |
|
|
|
Benign Prostate Hyperplasia (BPH) |
|
|
|
Alpha Adrenergic Receptor Blocking Agents (Alpha Blockers)
Therapeutics that increase blood flow by acting on the alpha adrenergic receptors thus causing the smooth muscle in the prostate to relax and decreasing the constriction on the urinary tract.
Target Products:
|
|
|
|
Testicular |
|
|
|
Failure |
|
|
|
Hormonal Treatments |
|
|
|
Androgens
Therapeutics that treat testicular failure by providing male sex hormones.
Target Products:
|
|
|
|
Hypogonadism |
|
|
|
Androgens
Therapeutics that treat hypogonadism by providing male sex hormones.
Target Products:
|
|
|
|
Phase I/Phase II Clinical Stage Products
Therapeutics that are being investigated for the treatment of urological disorders in early stages of clinical research where human subject is involved.
Target Products:
|
|
|
|
Urological Disorders |
|
|
|
Bladder |
|
|
|
Neurogenic Bladder Disease |
|
|
|
Anticholinergic Agents
Therapeutics that block the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Urinary Frequency/Urge Incontinence |
|
|
|
Anticholinergic Agents
Therapeutics that treat the inability to control urinary excretory functions by blocking the actions of choline and other cholinergic agents.
Target Products:
|
|
|
|
Kidney (Renal) |
|
|
|
Chronic Renal Failure (CRF) |
|
|
|
Complications |
|
|
|
Edema |
|
|
|
Potassium Sparing Diuretic Agents/Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium and water, but not potassium in urine.
Target Products:
|
|
|
|
Thiazide Diuretic Agents
Therapeutics that treat the accumulation of abnormally large amounts of fluid in subcutaneous tissue by increasing the excretion of sodium, potassium ions, and water in urine.
Target Products:
|
|
|
|
Nephrolithiasis/Renal Calculi (Kidney Stones) |
|
|
|
Calcium |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that treat the formation of kidney stones from calcium deposits by reducing uric acid formation through the inhibition of xanthine oxidase.
Target Products:
|
|
|
|
Uric Acid |
|
|
|
Xanthine Oxidase Inhibitors
Therapeutics that inhibit the conversion of hypoxanthine to uric acid, thus preventing the deposition of excess uric acid in the kidneys.
Target Products:
|
|
|
|
Weight Management |
|
|
|
Obesity |
|
|
|
Sympathomimetic Agents
Therapeutics that suppress appetite by stimulating the adrenergic receptors and produce adrenergic chemicals.
Target Products:
|
|
|
|
Research/Preclinical Stage Products
Therapeutics that are being investigated for the treatment of weight disorders in very early stages of research where no human subject is involved.
Buyer Products:
|
|
|
|
Wound Management |
|
|
|
Burns |
|
|
|
Complications |
|
|
|
Infections |
|
|
|
Antibacterial Agents (Antibiotics) |
|
|
|
Sulfonamides
Therapeutics that treat bacterial infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Antifungal Agents |
|
|
|
Sulfonamides
Therapeutics that treat fungal infections in injuries caused by fire or excessive heat by inhibiting folic acid synthesis.
Target Products:
|
|
|
|
Healthcare Services |
|
|
|
Distributors |
|
|
|
Pharmaceutical |
|
|
|
Specialty/Generic
Specialty drug distributors focus on the distribution of specific drugs. Because specialty drug distributors typically target certain therapeutic areas, in addition to distributing only certain classes of drugs, these companies will provide complementary services to the targeted patient populations. Examples of such complementary services include disease management programs, drug therapies (such as infusion therapy), and other disease class-specific services.
Target Products:
|
|
|
|
Medical Devices |
|
|
|
Drug Delivery |
|
|
|
Transdermal |
|
|
|
Patches
Medical patches applied to the skin which mediate sustained release of medications through the skin
Target Products:
|
|
|
|
Medical Supplies |
|
|
|
Treatment |
|
|
|
Wound Management/First Aid |
|
|
|
Drainage/Hydration
Medical devices designed to irrigate, moisturize and remove excess fluids from wounds and wound surface.
Buyer Products:
|
|
|
|
Ophthalmology |
|
|
|
Treatment |
|
|
|
Dry Eye |
|
|
|
Lubricants
Devices used to alleviate low level of moisture in eye tissue by adding fluid.
Target Products:
|
|
|
|
Nutritional Health |
|
|
|
Dietary/Naturopathic Supplements |
|
|
|
General Health
Products consisting of dietary/naturopathic supplements that are intended to support general health.
Target Products:
|
|
|
|
Women`s Health
Products consisting of dietary/naturopathic supplements that are intended to support women's health.
Target Products:
|
|
|
|
Outsourced Services |
|
|
|
Analytical Services
The Analytical Services Subsector includes outsourced services that utilize analytical instruments to analyze biological and chemical samples.
Target Products:
|
|
|
|
Development/Manufacturing Services |
|
|
|
Chemistry Services
Outsourced companies that provide medicinal chemistry, organic synthesis, process research, cGMP synthesis, and analytical services to the biopharmaceutical industry.
Target Products:
|
|
|
|
Contract Manufacturing Organizations (CMO) |
|
|
|
Pharmaceuticals |
|
|
|
Active/Intermediate Chemicals
Intermediate and active ingredient contract manufacturing organizations that produce large quantities of small molecule compounds for use in final dosage forms.
Target Products:
|
|
|
|
Final Dosage Forms
Contract Manufacturing Organizations (CMO) that produce large quantities of drug products in final dosage forms ready to be sold to end users.
Target Products:
|
|
|
|
Contract Research Organizations (CRO) |
|
|
|
Limited Service |
|
|
|
Preclinical
Limited Service Contract Research Organizations that design, manage, and monitor animal studies of new therapeutics. In addition to animal studies, these limited service companies also provide formulation development services.
Target Products:
|
|
|
|
Drug Delivery Technology |
|
|
|
Oral Delivery |
|
|
|
Hydrogel Based
Drug Delivery Technologies used to deliver drugs in a jelly like base.
Target Products:
|
|
|
|
Hydrogel Based/Polymer Coated
Drug Delivery Technologies used to deliver drugs in a jelly like base which are enclosed using a polymer matrix.
Target Products:
|
|
|
|
Osmotic
Drug Delivery Technologies utilizing an osmotic mechanism for sustained release of the drugs.
Target Products:
|
|
|
|
Polymer Coated
Drug Delivery Technologies used to deliver drugs in a polymer based matrix to hold/enclose the drug.
Target Products:
|
|
- Focused. Denotes that the company is considered focused in this area. In general, Focused Companies draw the majority of their earnings in the sector/product area specified.
- Sector Pure-Plays. Denotes that the company is focused in the selected sector and generates nearly all earnings in the sector/product area specified.
- Sector Participation. Denotes that the company develops products in this line of business.
Relationship Details
Key Competitors
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
Novartis AG (ADR)
|
|
n/a | 124,193.276 | 15.01 | 17.03 | 3.26 | 3.28 | 4.38 | |
|
QLT Inc. (USA)
|
|
n/a | 360.416 | 0.00 | 36.00 | 2.66 | 2.84 | 2.10 | |
|
Spectrum Pharmaceuticals, Inc.
|
|
n/a | 93.662 | 0.00 | -2.62 | 7.09 | 12.09 | 1.58 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 145,773.068 | 18.44 | 17.11 | 3.62 | 3.63 | 5.42 | |
| Target | |||||||||
|
Johnson & Johnson
|
|
n/a | 194,684.846 | 18.77 | 16.30 | 3.31 | 3.18 | 13.84 | |
|
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
Novartis AG (ADR)
|
|
n/a | 124,193.276 | 15.01 | 17.03 | 3.26 | 3.28 | 4.38 | |
|
Bayer AG (ADR)
|
|
n/a | 68,439.175 | 9.49 | 17.15 | 1.50 | 1.45 | n/a | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 34,509.881 | 18.74 | 19.29 | 3.79 | 3.67 | 12.79 | |
|
Covidien Ltd.
|
|
n/a | 22,365.204 | 0.00 | 17.20 | 2.20 | 2.04 | n/a | |
|
Shire plc (ADR)
|
|
n/a | 12,647.906 | 0.00 | 29.96 | 5.73 | 5.33 | n/a | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,853.007 | 0.00 | 17.79 | 2.42 | 2.29 | n/a | |
|
Endo Pharmaceuticals
|
|
n/a | 3,621.029 | 18.90 | 14.98 | 3.48 | 3.37 | 3.68 | |
|
Mylan Inc.
|
|
n/a | 3,360.037 | 11.44 | 11.46 | 1.76 | 1.31 | 3.58 | |
|
Perrigo Company
|
|
n/a | 3,279.033 | 36.06 | 24.29 | 2.20 | 1.99 | 8.54 | |
|
Biovail Corporation (USA)
|
|
n/a | 2,165.769 | 6.27 | 7.60 | 2.29 | 2.61 | 3.47 | |
|
Axcan Pharma Inc. (USA)
|
|
n/a | 1,248.360 | 17.47 | 17.14 | 3.58 | 3.63 | 4.22 | |
|
Auxilium Pharmaceuticals, Inc.
|
|
n/a | 1,236.202 | 0.00 | -28.38 | 14.13 | 12.76 | 17.05 | |
|
Valeant Pharmaceuticals International
|
|
n/a | 1,055.468 | 0.00 | 26.09 | 1.18 | 1.16 | n/a | |
|
AMAG Pharmaceuticals, Inc.
|
|
n/a | 1,053.828 | 0.00 | -28.76 | 379.08 | 371.35 | 3.62 | |
|
MannKind Corporation
|
|
n/a | 853.758 | 0.00 | -2.16 | 115,890.41 | 141.35 | 4.75 | |
|
Par Pharmaceutical Companies, Inc.
|
|
n/a | 754.274 | 14.04 | 14.69 | 0.99 | 0.94 | 2.03 | |
|
Eurand N.V.
|
|
n/a | 664.768 | 0.00 | -103.93 | 5.44 | 6.30 | 8.19 | |
- Defined by the Company
- Defined by Others
Dependent Suppliers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Gilead Sciences, Inc.
|
|
n/a | 43,243.667 | 0.00 | 27.50 | 10.72 | 10.11 | 15.16 | |
|
ISIS Pharmaceuticals, Inc.
|
|
n/a | 1,413.812 | 0.00 | -10.37 | 24.87 | 20.92 | n/a | |
|
Phase Forward Incorporated
|
|
n/a | 932.144 | 49.04 | 44.89 | 7.36 | 6.71 | 5.56 | |
|
Nektar Therapeutics
|
|
n/a | 643.458 | 0.00 | -6.71 | 2.32 | 2.42 | 7.19 | |
|
Enzon Pharmaceuticals, Inc.
|
|
n/a | 423.598 | 6.12 | -24.87 | 2.29 | 2.26 | n/a | |
|
Degussa AG
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
Novartis AG (ADR)
|
|
n/a | 124,193.276 | 15.01 | 17.03 | 3.26 | 3.28 | 4.38 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 10,223.910 | 0.00 | -33.08 | 14.45 | 13.50 | n/a | |
|
Warner Chilcott Ltd.
|
|
n/a | 4,430.245 | 6,553.00 | 16.58 | 5.04 | 4.95 | n/a | |
|
Mylan Inc.
|
|
n/a | 3,360.037 | 11.44 | 11.46 | 1.76 | 1.31 | 3.58 | |
|
Perrigo Company
|
|
n/a | 3,279.033 | 36.06 | 24.29 | 2.20 | 1.99 | 8.54 | |
|
Genelabs Technologies
|
|
n/a | 57.708 | 0.00 | -6.48 | 3.49 | 3.96 | 4.80 | |
- Defined by the Company
- Defined by Others
Key Customers
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Buyer | |||||||||
|
Merck & Co., Inc.
|
|
n/a | 128,743.940 | 23.93 | 18.70 | 5.36 | 5.25 | 6.95 | |
|
Eli Lilly & Co.
|
|
n/a | 61,513.794 | 27.57 | 15.08 | 3.48 | 3.31 | 5.86 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 55,358.738 | 26.11 | 19.10 | 2.97 | 2.80 | 11.80 | |
| Target | |||||||||
|
McKesson Corporation
|
|
17.00% | 19,082.199 | 19.43 | 19.52 | 0.20 | 0.19 | 6.07 | |
|
AmerisourceBergen Corp.
|
|
13.00% | 7,482.672 | 15.95 | 15.20 | 0.11 | 0.11 | 683.97 | |
|
Cardinal Health, Inc.
|
|
9.00% | 21,169.519 | 10.79 | 14.71 | 0.24 | 0.23 | 17.00 | |
|
Walgreen Company
|
|
8.00% | 38,137.008 | 18.68 | 16.48 | 0.71 | 0.60 | 3.66 | |
|
sanofi-aventis (ADR)
|
|
n/a | 126,998.372 | 21.72 | 12.36 | 2.93 | 3.15 | n/a | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 34,509.881 | 18.74 | 19.29 | 3.79 | 3.67 | 12.79 | |
|
Covidien Ltd.
|
|
n/a | 22,365.204 | 0.00 | 17.20 | 2.20 | 2.04 | n/a | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,853.007 | 0.00 | 17.79 | 2.42 | 2.29 | n/a | |
|
Sciele Pharma Inc.
|
|
n/a | 779.277 | 15.24 | 13.21 | 2.18 | 2.01 | 623.42 | |
|
Takeda Pharmaceutical Company Limited
|
|
n/a | 0.000 | 0.00 | n/a | 0.00 | n/a | n/a | |
|
Government - United States
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Key Partners
| Name | Dir | Percent | Market Cap. | P/E Ratio (TTM) | Fwd P/E | P/R Ratio (TTM) | Fwd P/Rev | Price To Tang. Book Value | |
|---|---|---|---|---|---|---|---|---|---|
| Overlap | |||||||||
|
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 55,358.738 | 26.11 | 19.10 | 2.97 | 2.80 | 11.80 | |
| Buyer | |||||||||
|
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
Roche Holding Ltd. (ADR)
|
|
n/a | 145,773.068 | 18.44 | 17.11 | 3.62 | 3.63 | 5.42 | |
|
Merck & Co., Inc.
|
|
n/a | 128,743.940 | 23.93 | 18.70 | 5.36 | 5.25 | 6.95 | |
| Target | |||||||||
|
Pfizer Inc.
|
|
n/a | 158,724.669 | 10.68 | 10.80 | 3.30 | 3.33 | 6.50 | |
|
sanofi-aventis (ADR)
|
|
n/a | 126,998.372 | 21.72 | 12.36 | 2.93 | 3.15 | n/a | |
|
Novartis AG (ADR)
|
|
n/a | 124,193.276 | 15.01 | 17.03 | 3.26 | 3.28 | 4.38 | |
|
Bristol Myers Squibb Co.
|
|
n/a | 55,358.738 | 26.11 | 19.10 | 2.97 | 2.80 | 11.80 | |
|
Teva Pharmaceutical Industries Ltd (ADR)
|
|
n/a | 34,509.881 | 18.74 | 19.29 | 3.79 | 3.67 | 12.79 | |
|
Solvay S.A. (ADR)
|
|
n/a | 11,684.521 | 10.92 | n/a | 0.86 | n/a | 3.28 | |
|
Elan Corporation, plc (ADR)
|
|
n/a | 10,223.910 | 0.00 | -33.08 | 14.45 | 13.50 | n/a | |
|
Barr Pharmaceuticals, Inc.
|
|
n/a | 5,853.007 | 0.00 | 17.79 | 2.42 | 2.29 | n/a | |
|
Warner Chilcott Ltd.
|
|
n/a | 4,430.245 | 6,553.00 | 16.58 | 5.04 | 4.95 | n/a | |
|
Mylan Inc.
|
|
n/a | 3,360.037 | 11.44 | 11.46 | 1.76 | 1.31 | 3.58 | |
|
Perrigo Company
|
|
n/a | 3,279.033 | 36.06 | 24.29 | 2.20 | 1.99 | 8.54 | |
|
Medarex, Inc.
|
|
n/a | 1,403.802 | 0.00 | -47.96 | 29.81 | 29.94 | 2.86 | |
|
Savient Pharmaceuticals, Inc.
|
|
n/a | 1,158.552 | 0.00 | -23.70 | 56.90 | 77.70 | 7.69 | |
|
Sciele Pharma Inc.
|
|
n/a | 779.277 | 15.24 | 13.21 | 2.18 | 2.01 | 623.42 | |
|
DepoMed, Inc.
|
|
n/a | 162.400 | 11.23 | 4.36 | 2.49 | 2.60 | 8.26 | |
|
Genelabs Technologies
|
|
n/a | 57.708 | 0.00 | -6.48 | 3.49 | 3.96 | 4.80 | |
|
Interpharm Holdings, Inc.
|
|
n/a | 26.028 | 0.00 | n/a | 0.37 | n/a | 1.21 | |
|
Takeda Pharmaceutical Company Limited
|
|
n/a | 0.000 | 0.00 | n/a | 0.00 | n/a | n/a | |
|
Amphastar Pharmaceuticals, Inc.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
|
Cipla Ltd.
|
|
n/a | n/a | n/a | n/a | n/a | n/a | n/a | |
- Defined by the Company
- Defined by Others
Financials
| Buyer | Target | Combined Entity | |
|---|---|---|---|
| Income Statement | |||
| Operating Items | |||
| Revenue | 334.3 | 2,490.5 | 2,824.7 |
|
Other Revenue
|
5.7 | 0.0 | 5.7 |
| Total Revenue | 340.0 | 2,490.5 | 2,830.5 |
|
Cost of Revenue
|
39.4 | 1,541.6 | 1,581.0 |
|
SG&A Expense
|
114.7 | 415.9 | 530.6 |
|
Depreciation & Amortization
|
6.4 | 174.4 | 180.7 |
|
Research & Development
|
131.0 | 149.6 | 280.6 |
|
Interest Expense
|
0.0 | 0.0 | 0.0 |
|
Other Operating Expense
|
1.1 | -6.1 | -5.0 |
|
Unusual Expense (Income)
|
193.2 | 505.5 | 698.7 |
| Total Expenses | 485.8 | 2,780.8 | 3,266.6 |
|
Operating Income
|
-145.8 | -290.3 | -436.1 |
| Non Operating Items | |||
|
Interest Expense (Inc.), Net Non-Oprtng
|
7.3 | -29.4 | -22.0 |
|
Gain/Loss On Sale Of Assets
|
0.0 | 2.5 | 2.5 |
|
Other, Net
|
0.2 | 0.5 | 0.6 |
| Income Before Taxes | -138.3 | -316.7 | -455.0 |
| Income Taxes | 0.0 | 69.6 | 69.6 |
| Income After Taxes | -138.3 | -386.3 | -524.6 |
|
Net Income - Excl. Xord. Items
|
-138.3 | -386.3 | -524.6 |
| Discontinued Operations | -29.0 | 0.0 | -29.0 |
|
Net Income - Incl. Xord. Items
|
-167.3 | -386.3 | -553.6 |
|
Income Avail. to Common
|
-167.3 | -386.3 | -553.6 |
| Share Items | |||
|
Basic Avg. Shares Outstanding
|
57.8 | 102.5 | 160.2 |
|
Basic EPS - Excl. Xord. Items
|
n/a | n/a | -3.27 |
|
Basic EPS - Incl. Xord. Items
|
n/a | n/a | -3.46 |
| Full Dilution Adjustment | 0.0 | 1.9 | 1.9 |
| Fully Diluted Shares Outstanding | 65.2 | 117.4 | 182.6 |
|
F.D. EPS - Excl. Xord. Items
|
n/a | n/a | -2.87 |
|
F.D. EPS - Incl. Xord. Items
|
n/a | n/a | -3.03 |
| Balance Sheet | |||
| Assets | |||
|
Cash and Equivalents
|
99.3 | 133.3 | 232.6 |
|
ST Investments
|
181.9 | 11.7 | 193.7 |
|
Accounts Receivable
|
80.7 | 275.8 | 356.6 |
|
Inventory
|
22.0 | 524.1 | 546.1 |
|
Prepayments and Advances
|
5.7 | 81.8 | 87.4 |
|
Other Current Assets
|
42.2 | 97.2 | 139.5 |
|
Current Assets
|
431.9 | 1,124.0 | 1,555.9 |
|
Accum D&A
|
0.0 | 0.0 | 0.0 |
|
PPE, Net
|
47.3 | 683.4 | 730.8 |
| Goodwill & Intangibles | 45.0 | 1,523.0 | 1,568.0 |
| Long Term Investments | 0.0 | 70.3 | 70.3 |
| Other Assets | 0.0 | 0.0 | 0.0 |
|
Other LT Assets
|
8.8 | 54.6 | 63.4 |
| Total Assets | 533.1 | 3,455.3 | 3,988.3 |
| Liabilities | |||
| Accounts Payable | 0.0 | 0.0 | 0.0 |
| Payable/Accrued | 50.0 | 371.4 | 421.5 |
|
ST Debt
|
0.0 | 0.0 | 0.0 |
|
Curr Port of LTD & Cap Lease Oblg
|
150.0 | 6.6 | 156.6 |
| Other (Current) Liabilities | 56.1 | 16.9 | 73.1 |
|
Current Liab.
|
256.2 | 394.9 | 651.1 |
|
LT Debt
|
115.0 | 974.3 | 1,089.3 |
|
Total LT Debt
|
115.0 | 974.3 | 1,089.3 |
| Deferred Taxes | 0.0 | 172.9 | 172.9 |
|
Other LT Liab.
|
51.2 | 106.1 | 157.4 |
|
Total Liabilities
|
422.4 | 1,648.3 | 2,070.7 |
| Shareholders Equity | |||
| Common Stock | 0.6 | 0.4 | 1.0 |
| Additional Paid in Capital | 1,639.8 | 963.8 | 2,603.7 |
| Retained Earnings | -1,498.1 | 1,141.3 | -356.8 |
| Treasure Stock | -37.2 | -301.7 | -339.0 |
| Other Equity | 5.6 | 3.2 | 8.8 |
|
Total Equity
|
110.6 | 1,807.0 | 1,917.6 |
|
Total Liab. & Equity
|
533.1 | 3,455.3 | 3,988.3 |
|
Shares Outstanding
|
57.7 | 103.6 | 161.3 |
| Cash Flow | |||
| Operating Cash Flow | |||
| CF Net Income | -167.3 | -386.3 | -553.6 |
| CF Depreciation | 17.3 | 74.5 | 91.8 |
| CF Amortization | 185.7 | 174.4 | 360.1 |
| CF Deferred Taxes | 0.0 | 13.9 | 13.9 |
| Other Non-Cash Items | 46.3 | 561.8 | 608.1 |
| Change in Working Capital | -19.8 | -49.0 | -68.8 |
| Total Cash From Operating Activities | 62.2 | 389.3 | 451.6 |
| Investing Cash Flow (not calculated) | |||
| Capital Expenditures | -4.5 | -69.4 | -73.9 |
| Other Investing Cash Flows | -34.8 | -1,329.8 | -1,364.5 |
| Total Cash From Investing Activities | -39.3 | -1,399.2 | -1,438.4 |
| Financing Cash Flow (not calculated) | |||
| Dividends Paid | 0.0 | 0.0 | 0.0 |
| Purchase Or Sale of Stock | 15.4 | 13.7 | 29.0 |
| Purchase and Retirement of Debt | -0.0 | 394.3 | 394.3 |
| Other Financing Cash Flow | 0.0 | 0.0 | 0.0 |
| Total Cash From Financing Activities | 15.3 | 408.0 | 423.3 |
| Exchange Rate Effects | 0.7 | 0.0 | 0.7 |
| Net Change in Cash | 39.0 | -601.9 | -562.9 |
| Cash Taxes Paid | 0.0 | 63.8 | 63.8 |
| Cash Interest Paid | 3.6 | 12.6 | 16.2 |